Business
AZN invests $2.5bn in Beijing R&D & manufacturing
AZN invests $2.5bn in Beijing R&D & manufacturing.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n\n21 March 2025\n \nAstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing\n \nAstraZeneca is establishing a new global strategic R&D centre in Beijing, its second in China and sixth worldwide\n \nInvestment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai\n \nAstraZeneca today announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manufacturing agreements that will further advance life sciences in China. This investment over the next five years is part of a strategic partnership with the Beijing Municipal Government and the Beijing Economic-Technological Development Area Administrative Office and includes agreements with three biotechs; Harbour BioMed, Syneron Bio, and BioKangtai, and follows the recent Fibrogen announcement. AstraZeneca expects its Beijing workforce to grow to 1,700 employees.\n \nPascal Soriot, Chief Executive Officer, AstraZeneca, said: This $2.5 billion investment reflects our belief in the world-class life sciences ecosystem in Beijing, the extensive opportunities that exist for collaboration and access to talent, and our continued commitment to China. Our sixth strategic R&D centre will partner with the cutting-edge biology and AI science in Beijing and be a critical part of our global efforts to bring innovative medicines to patients worldwide.\n \nThe new global strategic R&D centre in Beijing, AstraZeneca's second in China following the opening of the Shanghai R&D centre, will advance early-stage research and clinical development and will be enabled by a new state-of-the-art AI and data science laboratory. The new R&D centre will be located near leading biotechs, research hospitals, and the National Medical Products Administration in the Beijing International Pharmaceutical Innovation Park (BioPark). \n \nAstraZeneca is also establishing new R&D collaborations in Beijing. This includes a strategic partnership with the Beijing Cancer Hospital in translational research, data science, and clinical development. AstraZeneca is signing two collaboration and licensing agreements; one with Harbour BioMed to discover multi-specific antibodies, and one with Syne...